Figure 3.
Model structure of CMY-185. (a) Overall structure of CMY-185. The substitution residues are shown as CPK representations coloured in magenta. To clarify the substrate-binding site, the ceftazidime molecule is shown as a white ball-and-stick representation. (b, c) Close-up views of the model structures of the CMY-185 complex with ceftazidime (b) or avibactam (c). (d, e) Close-up views of the crystal structures of the AmpCEnt385 complex with ceftazidime (d, PDB accession number 6LC9) or avibactam (e, PDB accession number 6LC8). Hydrogen bonds are represented as orange dashed lines.

Model structure of CMY-185. (a) Overall structure of CMY-185. The substitution residues are shown as CPK representations coloured in magenta. To clarify the substrate-binding site, the ceftazidime molecule is shown as a white ball-and-stick representation. (b, c) Close-up views of the model structures of the CMY-185 complex with ceftazidime (b) or avibactam (c). (d, e) Close-up views of the crystal structures of the AmpCEnt385 complex with ceftazidime (d, PDB accession number 6LC9) or avibactam (e, PDB accession number 6LC8). Hydrogen bonds are represented as orange dashed lines.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close